184 related articles for article (PubMed ID: 1433176)
1. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
[TBL] [Abstract][Full Text] [Related]
2. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Kirby DA; Koerber SC; Craig AG; Feinstein RD; Delmas L; Brown MR; Rivier JE
J Med Chem; 1993 Feb; 36(3):385-93. PubMed ID: 8426366
[TBL] [Abstract][Full Text] [Related]
3. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Kirby DA; Boublik JH; Rivier JE
J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structure, and antagonistic properties of des-Asn29[D-Trp28,32]NPY(27-36).
Balasubramaniam A; Zhai W; Tao Z; Huang Y; Fischer JE; Eden P; Taylor JE; Kar L; Samarasinghe SD; Johnson ME
Peptides; 1996; 17(7):1113-8. PubMed ID: 8959744
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-potency neuropeptide Y analogues through systematic lactamization.
Kirby DA; Britton KT; Aubert ML; Rivier JE
J Med Chem; 1997 Jan; 40(2):210-5. PubMed ID: 9003519
[TBL] [Abstract][Full Text] [Related]
7. Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.
Grundemar L; Kahl U; Callréus T; Langel U; Bienert M; Beyermann M
Regul Pept; 1996 Apr; 62(2-3):131-6. PubMed ID: 8795076
[TBL] [Abstract][Full Text] [Related]
8. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
[TBL] [Abstract][Full Text] [Related]
9. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.
Tschöpl M; Miller RC; Pelton J; Stoclet JC; Bucher B
Br J Pharmacol; 1993 Nov; 110(3):1098-104. PubMed ID: 8298798
[TBL] [Abstract][Full Text] [Related]
10. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors.
Grandt D; Schimiczek M; Rascher W; Feth F; Shively J; Lee TD; Davis MT; Reeve JR; Michel MC
Regul Pept; 1996 Nov; 67(1):33-7. PubMed ID: 8952003
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent labelled analogues of neuropeptide Y for the characterization of cells expressing NPY receptor subtypes.
Ingenhoven N; Beck-Sickinger AG
J Recept Signal Transduct Res; 1997; 17(1-3):407-18. PubMed ID: 9029504
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems.
Cox HM; Tough IR; Ingenhoven N; Beck-Sickinger AG
Regul Pept; 1998 Sep; 75-76():3-8. PubMed ID: 9802388
[TBL] [Abstract][Full Text] [Related]
14. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
15. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.
Beck-Sickinger AG; Wieland HA; Wittneben H; Willim KD; Rudolf K; Jung G
Eur J Biochem; 1994 Nov; 225(3):947-58. PubMed ID: 7957231
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical neuropeptide Y receptor.
Monnet FP; Fournier A; Debonnel G; de Montigny C
J Pharmacol Exp Ther; 1992 Dec; 263(3):1212-8. PubMed ID: 1469629
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y1, Y2 and Y3 receptor sub-types.
Dumont Y; Satoh H; Cadieux A; Taoudi-Benchekroun M; Pheng LH; St-Pierre S; Fournier A; Quirion R
Eur J Pharmacol; 1993 Jul; 238(1):37-45. PubMed ID: 8405081
[TBL] [Abstract][Full Text] [Related]
18. A Y2 receptor mimetic aptamer directed against neuropeptide Y.
Proske D; Höfliger M; Söll RM; Beck-Sickinger AG; Famulok M
J Biol Chem; 2002 Mar; 277(13):11416-22. PubMed ID: 11756401
[TBL] [Abstract][Full Text] [Related]
19. The bioactive conformation of neuropeptide Y analogues at the human Y2-receptor.
Rist B; Ingenhoven N; Scapozza L; Schnorrenberg G; Gaida W; Wieland HA; Beck-Sickinger AG
Eur J Biochem; 1997 Aug; 247(3):1019-28. PubMed ID: 9288927
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
